Pineo Graham F, Hull Russell D
Thrombosis Research Unit, 601 South Tower-Foothills Hospital, 1403-1429 Street NW, Calgary, Alberta, T2N 2T9, Canada.
Expert Opin Pharmacother. 2003 Dec;4(12):2355-62. doi: 10.1517/14656566.4.12.2355.
Low molecular weight heparin (LMWH) has been widely used for the initial treatment of patients presenting with venous thromboembolism. The LMWH, tinzaparin, has been shown in randomised clinical trials to be as effective and safe as unfractionated heparin for the initial treatment of venous thromboembolism and in clinical trials, it has been used in place of warfarin for the long-term treatment of deep vein thrombosis. Tinzaparin can safely be given to patients with significant renal impairment (creatinine clearance of > or = 20 ml/min) and the dose of tinzaparin does not need to be altered in patients with a body mass index of > 25.
低分子量肝素（LMWH）已被广泛用于静脉血栓栓塞症患者的初始治疗。低分子量肝素替扎肝素在随机临床试验中已表明，在静脉血栓栓塞症的初始治疗中，其疗效和安全性与普通肝素相当，并且在临床试验中，它已被用于替代华法林进行深静脉血栓形成的长期治疗。替扎肝素可安全地给予有严重肾功能损害（肌酐清除率≥20 ml/分钟）的患者，且对于体重指数＞25的患者，替扎肝素的剂量无需调整。
